Table 1.
EMA and FDA approved gene-modified T cell therapies (accessed on 4 January 2021).
| INN 1 (Commercial Name) |
Manufacturer | Application(s) | Therapy Type | Market Approval | Price per Dose (USD 4) |
Reference | ||
|---|---|---|---|---|---|---|---|---|
| EMA 2 | FDA 3 | |||||||
| brexucabtagene autoleucel (Tecartus®) |
Kite Pharma Inc. (Gilead) | Mantle cell lymphoma | CAR T cellGRV vector | 2020 | 2020 | $ | 373,000 | [9,10] |
| tisagenlecleucel (Kymriah®) |
Novartis AG | Acute B-cell lymphoblastic leukaemia |
CAR T cellLV vector | 2018 | 2017 | $ | 475,000 | [5,6] |
| axicabtagene ciloleucel (Yescarta®) |
Kite Pharma Inc. (Gilead) | B cell lymphoma | CAR T cellGRV vector | 2018 | 2017 | $ | 373,000 | [7,8] |
1 International Non-proprietary Name—2 European Medicines Agency—3 Food and Drug Administration—4 United States Dollar.